Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping betwe...en the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.
TY - JOUR
AU - Stanojević, N
AU - Jelić-Ivanović, Zorana
AU - Durović, S
AU - Spasojević-Kalimanovska, Vesna
PY - 1999
UR - http://farfar.pharmacy.bg.ac.rs/handle/123456789/212
AB - Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.
PB - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2 - Jugoslovenska medicinska biohemija
T1 - The role of transforming growth factor-beta in identifying patients with coronary artery disease
VL - 18
IS - 2-3
SP - 85
EP - 89
ER -
@article{
author = "Stanojević, N and Jelić-Ivanović, Zorana and Durović, S and Spasojević-Kalimanovska, Vesna",
year = "1999",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/212",
abstract = "Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "The role of transforming growth factor-beta in identifying patients with coronary artery disease",
volume = "18",
number = "2-3",
pages = "85-89"
}
Stanojević N, Jelić-Ivanović Z, Durović S, Spasojević-Kalimanovska V. The role of transforming growth factor-beta in identifying patients with coronary artery disease. Jugoslovenska medicinska biohemija. 1999;18(2-3):85-89
Stanojević, N., Jelić-Ivanović, Z., Durović, S.,& Spasojević-Kalimanovska, V. (1999). The role of transforming growth factor-beta in identifying patients with coronary artery disease.
Jugoslovenska medicinska biohemijaDruštvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 18(2-3), 85-89.
Stanojević N, Jelić-Ivanović Zorana, Durović S, Spasojević-Kalimanovska Vesna, "The role of transforming growth factor-beta in identifying patients with coronary artery disease" 18, no. 2-3 (1999):85-89
